
WilmerHale Represents Akouos in Acquisition by Lilly

OCTOBER 19, 2022

On October 18, 2022, Eli Lilly and Company [announced](#) a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery and AAV gene therapy. The acquisition will enable the company to leverage Lilly's resources and global reach to further its mission of making healthy hearing available to all. Under the terms of the agreement, Lilly will commence a tender offer to acquire outstanding shares of Akouos for an aggregate purchase price of approximately \$487 million.

The WilmerHale team representing Akouos was led by [Rosemary G. Reilly](#), [Joseph Conahan](#), [Andrew Bonnes](#), [Molly Fox](#), [Will Myer](#), [Erin Garrity](#) and [Chris Gravalles](#).